Professor Curtis Huttenhower
Talk to me about… your research
I am a Professor in Biostatistics at the Harvard T.H. Chan School of Public Health and an Associate Member at the Broad Institute. I participated extensively in the NIH Human Microbiome Project and co-leads the "HMP2" Center for Characterizing the gut microbial ecosystem in IBD and the Human Microbiome Bioactives Resource. My lab focuses on computational methods for functional analysis of microbial communities. This includes systems biology reconstructions integrating metagenomic, metatranscriptomic, and other microbial community 'omics, the human microbiome in autoimmune disease such as IBD, and its potential as a biomarker and route for therapeutic intervention.
Talk to me about…something people may not know about you
I'm a happy kitty parent, most recently of two new kittens who (like human babies) have as yet to learn to sleep through the night. I wish I had as much energy as they do!
Dr. Gregor Reid
Dr. Gregor Reid is a professor of Microbiology and Immunology and Surgery at Western University, and the Endowed Chair in Human Microbiome and Probiotics at the Lawson Health Research Institute. Dr. Reid’s research interests include: Microbiome and probiotics, Women’s health, Environmental influences on health, and Genitourinary systems. Having been a pioneer of probiotic research and the study of microbes in the urogenital tract of women, his research has expanded to studies of the gut, breast, heart and use of probiotics to detoxify environmental pollutants. Dr. Gregor Reid’s research primarily focuses on beneficial microbes, and he is one of the world’s foremost experts on probiotics, (microorganisms that produce many health benefits). To date, he has developed novel probiotic therapies used by several million people around the world. He has also held 28 patents, published over 500 peer-reviewed publications, in highly prestigious academic journals including Lancet, JAMA, PNAS, PLoS One, Nature and Nature Reviews Microbiology; he has also given >600 talks in 54 countries, and has a Google Scholar H factor of 81.
Dr Jamie Lorimer
Jamie Lorimer joined the School of Geography and the Environment in October 2012. Jamie has a BSc (Hons, first class) and PhD from the University of Bristol. His PhD and subsequent post-doctoral fellowships at Oxford (2005-7) were funded by the ESRC. Prior to returning to Oxford, Jamie lectured for four years at Kings College London.
Jamie’s research interests encompass cultural geography, the geographies of science, the politics of Nature and wildlife conservation. His work explores inherently geographical questions that conjoin the social and the environmental sciences. He employs qualitative, visual, ethnographic and historical methods. He has conducted extensive periods of fieldwork in the UK, Sri Lanka and most recently the Netherlands. Jamie’s research has been funded by a series of grants from the ESRC and has been published in many of the leading geography and interdisciplinary journals. He has been a visiting researcher at the Universities of British Columbia and Peradeniya (Sri Lanka).
Professor Jeroen Raes
Jeroen Raes is group leader of the Bioinformatics and (eco-)Systems Biology (BSB) research group at VIB in Brussels. He has an extensive track record in meta-omics and microbiome research. He is associate editor for ISME journal, Scientific Reports (Nature publishing group), SIGS and Genomics Insights and is reviewer and/or committee member for ANR/NWO/FWO/ERC proposals.The Raes lab combines large-scale, next-generation sequencing with novel computational approaches to investigate the functioning and variability of the healthy human microbiome at the systems level and studies its alteration in disease.
Joseph Sliman
From January 13, 2014 until January 17, 2017, Dr. Sliman served as the Company’s Senior Vice President-Clinical & Regulatory Affairs. Dr. Sliman has more than 18 years of experience in clinical and public health research, including 10 years directing clinical projects and product development, in therapeutic areas such as infectious diseases and vaccines. From September 2012 until January 2014, Dr. Sliman served as Senior Medical Director and Head of Patient Safety and Pharmacovigilance at Vanda Pharmaceuticals Inc., where he directed efforts for a New Drug Application for HETLIOZ (tasimelteon), which is indicated for the treatment of Non-24 Hour Disorder in totally blind adults. From December 2008 until August 2012, Dr. Sliman served as Medical Director in Vaccines and Infectious Diseases at MedImmune, Inc., where he was a member of successful Biologics Licensure Application teams. Prior to joining MedImmune, Inc., he served as Associate Medical Director at Dynport Vaccine Company, where he was the clinical director for seasonal and pandemic influenza vaccine trials as well as its Defense Vaccines development program (partnered with Department of Defense Joint Vaccines Acquisition Program). During his service in the United States Navy, Dr. Sliman led the U. S. Pacific Fleet disease surveillance programs, including influenza surveillance, preparedness, and prevention, as well as communicable disease and injury surveillance and prevention and health policy development. Dr. Sliman earned an M.D. from the Uniformed Services University, a Master’s Degree in Public Health from the Johns Hopkins University School of Public Health, and a B.S. in Molecular and Cell Biology, with Honors in Biology, from Pennsylvania State University.
Professor Max Nieuwdorp
Dr Nieuwdorp is currently working as an internist-endocrinologist and Head of the department of Experimental Vascular Medicine at the Academic Medical Centre (AMC) within the University of Amsterdam. He has initiated a translational research group focused on dissecting the causal role of (small) intestinal bacterial strains to reverse insulin resistance, adipose tissue inflammation and cardiovascular disease. Dr Niuewdorp is also Visiting Professor at the University of Gothenburg. He has previously completed a residency in internal medicine and a fellowship at AMC Amsterdam and a postdoctoral fellowship in glycobiology at University College San Diego, USA.
Professor Tim Spector
Tim Spector is a Professor of Genetic Epidemiology and Director of the TwinsUK Registry at Kings College, London. He trained originally in rheumatology and epidemiology. In 1992 he moved into genetic epidemiology and founded the UK Twins Registry, of 13,000 twins, which is the richest collection of genotypic and phenotypic information worldwide. He is past President of the International Society of Twin Studies, directs the European Twin Registry Consortium (Discotwin) and collaborates with over 120 centres worldwide. He has demonstrated the genetic basis of a wide range of common complex traits, many previously thought to be mainly due to ageing and environment. Through genetic association studies (GWAS), his group have found over 500 novel gene loci in over 50 disease areas. He has published over 800 research articles and is ranked as being in the top 1% of the world’s most cited scientists by Thomson-Reuters as well as the most cited scientist at King’s College London. He held a prestigious European Research Council senior investigator award in epigenetics and is a NIHR Senior Investigator and is a Fellow of the UK Academy of Medical Sciences. His current work focuses on omics and the microbiome and directs the crowdfunded British Gut microbiome project. He is a prolific writer with several popular science books and a regular blog, focusing on genetics, epigenetics and most recently microbiome and diet (The Diet Myth). He is in demand as a public speaker and features regularly in the media.
Dr Trevor Lawley
Trevor obtained his PhD from the University of Alberta, Canada, where he studied the mechanisms that pathogenic bacteria use to disseminate antibiotic resistance genes. In 2010, Trevor was appointed as a Career Development Fellow in the Sanger Institute Faculty and was promoted to Group Leader in 2014. He receives funding from the Medical Research Council. Trevor’s research investigates the mechanisms that underlie how micro-organisms on mucosal surfaces (gut, nasopharnyx, uro-gential tract) interact with their host during periods of health and disease. In particular, he seeks to develop novel ways to treat diseases that are associated with unwanted imbalances in the micro-organism communities.
Professor David Berry
David Berry is Associate Professor at the University of Vienna.
His research interests include:
- Function of the intestinal microbiota in health and disease
- Numerical approaches to study microbial communities
- Development of molecular and isotope-labeling methods for studying uncultivated microorganisms in their natural environment
He has 28 publications in peer-reviewed journals, including in leading multidisciplinary and discipline-specific journals such as: Proc Natl Acad Sci USA, Cancer Res, FEMS Microbiol Rev, and ISME J.
David Kyle
Talk to me about… your research
I am the Chairman and CSO of Evolve Biosystems Inc and a 30-year veteran of biotech having co-founded a range of successful biotech companies in the fields of nutrition and health. These include Martek Biosciences that focuses on DHA and ARA nutrition for infants, which was acquired by DSM in 2011 for $1.1 Billion and Evolve BioSystems the leader in the field of the infant microbiome. I am trained as a biochemist and have spent most of my career working with mothers and babies, focusing specifically on infant nutrition.
Talk to me about…something people may not know about you
I am the named inventor on over 250 patents and was inducted into the US Technology Hall of Fame in 200 for my contributions to Science and Industry. I am passionately engaged in bringing new technologies into commerce to improve the life-long health trajectory of all infants worldwide